We investigated the effects of the angiogenesis inhibitor TNP-470 on human lung squamous cell carcinoma cell lines H226B and H226Br both in vivo and in vitro. Angiogenesis is an important process in solid cancer growth, progression, and metastasis.
Angiogenesis is an important process in solid cancer growth, progression, and metastasis. 1, 2) Recently, inhibition of angiogenesis has been used as a strategy for cancer therapy. The angiogenesis inhibitor TNP-470 is an analog of fumagillin derived from Aspergillus fumigatus. It strongly inhibits angiogenesis by the suppression of vascular endothelial cell proliferation. It has been reported that TNP-470 inhibits the cell cycle and suppresses the proliferation of vascular endothelial cells.
3) TNP-470 also has a direct inhibitory effect on cancer cells, [4] [5] [6] although the mechanism of this is not well understood. TNP-470 inhibits cancer proliferation and metastasis both in vitro and in vivo. [7] [8] [9] Previous studies have shown that thymidine phosphorylase (dThdPase) is identical to platelet-derived endothelial cell growth factor (PD-ECGF), which has an angiogenic function. [10] [11] [12] PD-ECGF/dThdPase is expressed in various tumors, including gastric, lung, breast, and bladder cancers, [13] [14] [15] [16] as well as in normal tissues. 17) Its expression plays an important role in cancer growth and metastasis, and influences the prognosis. 1, 18) In the present study, we investigated the effects of TNP-470 on human lung cancer cell lines by examining its effects on tumor growth, cell proliferation, expression of PD-ECGF/dThdPase, activity of PD-ECGF/dThdPase, and angiogenesis.
MATERIALS AND METHODS
Animals, cell lines and cell culture Female ICR nude mice (4 weeks old) were obtained from Charles River Japan, Inc. (Yokohama). The animals were used at 5 weeks of age. We also used two human lung cancer cell lines, H226B established from human lung squamous cell carcinoma, and H226Br established from brain metastatic lesion of H226B. H226B cells express wild-type p53 while H226Br cells express mutant-type p53. 19) These cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum, and cultured at 37°C in a 5% CO 2 incubator.
Preparation of TNP-470
The angiogenic inhibitor TNP-470, derived from fumagillin, which is a naturally secreted antibiotic of A. fumigatus Fresenius, 4) was a kind gift from Takeda Chemical Industries, Ltd. (Osaka). TNP-470 was suspended in a vehicle of 3% or 10% ethanol and 5% gum Arabic in saline in vivo. 20) It was dissolved in dimethylsulfoxide and diluted with culture medium in vitro. 21) Tumor growth inhibition by TNP-470 in vivo The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Okayama University Medical School. H226B cells (1×10 7 /body) in 0.2 ml of saline were inoculated on the right side of the back of mice, and H226Br cells (1×10 7 /body) in 0.2 ml of saline were inoculated on the left side. TNP-470 was administered subcutaneously at a concentration of 100 mg/kg every other day. Control mice were injected with the vehicle only (10% ethanol and 5% gum Arabic in saline). Eight mice were used in each group. In another series of experiments, H226B or H226Br cells (1×10 7 / body) in 0.2 ml of saline were inoculated on the right side of the back of the mice. TNP-470 was administered subcutaneously at 30 mg/kg every other day. Control mice were injected with the vehicle only (3% ethanol and 5% gum Arabic in saline). Tumor volume was calculated as follows:
where a is the longest and b is the shortest diameter of the tumor.
8)
Immunohistochemical study We used DAKO EPOS anti-von Willebrand factor/HRP monoclonal antibody (DAKO Japan, Kyoto) to quantitate the extent of vascularization in tumor tissues obtained from mice treated with or without 30 mg/kg of TNP-470, by using the indirect immunoperoxidase method. Paraffin-embedded tissue samples were sectioned at 4 µm thickness and mounted on glass slides. The deparaffinized sections were incubated with 3% H 2 O 2 in distilled water for 5 min. After having been washed with Tris-buffered saline (TBS, 0.05 M Tris/HCl, 0.15 M NaCl, pH 7.6), the sections were incubated with a proteolytic enzyme (trypsin) for 30 min at 37°C. After another washing with TBS, the sections were incubated with first antibodies for 60 min at room temperature. After further washing with TBS, the sections were incubated with the chromogenic substrate solution for 5 min. Finally, the sections were counterstained with Mayer's hematoxylin, mounted and coverslipped.
22)
Cell growth inhibition by TNP-470 H226B and H226Br cells were seeded in 6-well plates at 5×10 4 cells/well. TNP-470 diluted with the culture medium to a concentration of 0, 0.1, 1, or 10 µg/ml was added to each well on day 0. Viable cells were counted on day 2, 4 or 6 by the dye-uptake method. Immunoblotting Cultured H226B and H226Br cells were harvested and directly resolved in sodium dodecyl sulfate (SDS) sample buffer (125 mM Tris, pH 6.8, 4% SDS, 20% glycerol, and 0.2% bromophenol blue). Equivalent amounts of total proteins obtained from direct lysis were loaded on 12% SDS polyacrylamide gels and transferred to a nitrocellulose membrane (Schleicher & Schuell Inc., Keene, NH). The membrane was blocked for 1 h at 37°C by rocking in TBS/milk buffer containing 50 mM Tris pH 7.0, 150 mM NaCl, and 5% skimmed milk. The membrane was incubated for 8 h at room temperature with the primary antibody in TBS/milk buffer. Anti-human basic fibroblast growth factor (bFGF) antibody, anti-human vascular endothelial cell growth factor (VEGF) antibody and anti-human PD-ECGF antibody (R&D Systems, Minneapolis, MN) were used as primary antibodies. Proteins were visualized using alkaline phosphatase-conjugated secondary antibody. 23) Lysates were also obtained from in vivo tissue samples by homogenization and the expressions of angiogenic factors were studied. dThdPase enzyme assay The activity of dThdPase was measured by the method described by Nishida et al. 24) Tissue samples were first homogenized in 10 mM Tris-HCl buffer (pH 7.4) containing 15 mM NaCl, 1.3 mM MgCl 2 and 50 mM potassium phosphate, and then centrifuged at 105 000g for 90 min. The supernatant was dialyzed overnight against 20 mM potassium phosphate buffer (pH 7.4) and 1 mM 2-mercaptoethanol, and was then used as a source of crude dThdPase. The dThdPase reaction mixture (120 µl) contained 183 mM potassium phosphate (pH 7.4), 10 mM 5′-deoxy-5-fluorouridine, and the crude enzyme from tissue samples. The reaction was carried out at 37°C for 60 min, and the amount of 5-fluorouracil generated was measured after its separation from 5′-deoxy-5-fluorouridine in an ERC-ODS-1171 HPLC column, with 50 mM sodium phosphate buffer (pH 6.8) containing 5 mM 1-decanesulfonic acid:methanol=85:15 (v/v).
Statistical analysis
All data were expressed as mean±SEM. Differences between groups were examined for statistical significance using Student's t test. A P value less than 0.05 was taken to indicate a statistically significant difference.
RESULTS

TNP-470 inhibits tumor growth in vivo
At 56 days after inoculation, the average volume of H226Br tumors was 1937 mm 3 while that of H226B tumors was smaller (463 mm 3 ). Tumor growth of H226Br was significantly more rapid than that of H226B (P<0.05). At a concentration of 30 mg/kg, TNP-470 suppressed the growth of both tumors, although the effect was greater on H226Br ( Fig. 1) . TNP-470 reduces body weight Loss of body weight, the major side effect of TNP-470, was observed when the angiogenic inhibitor was used at a dose of 100 mg/kg. At 56 days after inoculation, the mean body weights of naive, control and treated mice were 28, 25.2 and 19 g, respectively. This side effect was not observed when the dose of TNP-470 was 30 mg/kg. TNP-470 suppresses tumor vascularization Tissue sam- ples were harvested on day 56 and immunostained with anti-von Willebrand factor/HRP monoclonal antibody.
Marked vascularization was noted in control H226Br tumors ( Fig. 2A) . Vascularization was suppressed in mice treated with 30 mg/kg of TNP-470 (Fig. 2B ). H226B
tumors showed less extensive vascularization (Fig. 2C ) and the effect of the same dose of TNP-470 was less marked (Fig. 2D) . TNP-470 inhibits cell growth in vitro TNP-470 significantly suppressed the growth of H226Br cells in vitro when used at a concentration of 1 µg/ml (P<0.05) or 10 µg/ml (P<0.05) (Fig. 3A) . H226B cell growth was also suppressed by treatment with TNP-470 (Fig. 3B) .
TNP-470 suppresses PD-ECGF expression on H226Br
We also examined the expression of angiogenic factors on H226B and H226Br cells in vitro. Immunoblot analysis using anti-human PD-ECGF antibody showed a stronger signal of PD-ECGF in H226Br cells than in H226B cells (Fig. 4A) . On the other hand, the expression of bFGF was not evident in H226B or H226Br cells, while the expression of VEGF was similar in the two cell lines. The addition of TNP-470 reduced the expression of PD-ECGF/ dThdPase in H226Br dose-dependently, but had no effect on the expression in H226B cells (Fig. 4B) . TNP-470 did not influence the expression of VEGF in H226B or H226Br cells (Fig. 4C) .
TNP-470 suppresses PD-ECGF expression in H226Br tumors
We performed immunoblot analysis to examine the in vivo expression of PD-ECGF and VEGF in H226B and H226Br. Immunoblotting using anti-human PD-ECGF antibody showed PD-ECGF expression in both H226Br and H226B tumors. Treatment with TNP-470 reduced the expression of PD-ECGF/dThdPase in H226Br, but not in H226B. On the other hand, the expression of VEGF was similar in both H226B and H226Br tumors and TNP-470 did not influence the expression of VEGF in either case (Fig. 5) . TNP-470 suppresses the activity of dThdPase Finally, we investigated the activity of dThdPase in H226B and H226Br tumors in mice treated with 30 mg/kg of TNP-470 for 56 days. The activity of dThdPase in H226Br tumor was 92 units/mg protein in the control group, but significantly decreased to 47 units/mg protein during treatment with TNP-470 (P<0.05) (Fig. 6A) . On the other hand, the activity of dThdPase in H226B was not suppressed by TNP-470 treatment (Fig. 6B) .
DISCUSSION
Angiogenesis plays an important role in the growth of solid tumors, 1, 25) and exerts various effects on tumor progression, invasion, and metastasis. Several angiogenic factors have been reported, and the inhibition of neoangio- The angiogenesis inhibitor TNP-470 is an analog of fumagillin derived from A. fumigatus. It mainly acts by strongly suppressing the proliferation of vascular endothelial cells. Previous studies have shown that the latter effect of TNP-470 on vascular endothelial cells is due to inhibition of the cell cycle. TNP-470 also inhibits cancer cell growth through a direct effect on tumor cells. 4) Although the mechanism of this effect has not yet been established, inhibition of myristoylation of nitric oxide synthase is one possibility.
26) It is reported that TNP-470 inhibits the growth of gastric, 9) breast, prostate, 27) and colorectal 21) cancers, both in vitro and in vivo. TNP-470 also inhibits liver metastatic cancers 7, 9, 21, 28) and the combined use of TNP-470 and an anticancer agent is effective in inhibiting cancer metastasis. 29) In this study, we investigated the effect of TNP-470 on human lung cancer cell lines H226B and H226Br both in vivo and in vitro. Our results showed that inoculation of tumor cells resulted in a rapid growth of H226Br tumors compared to H226B. Nude mice inoculated with these cells were injected subcutaneously with 30 mg/kg of TNP-470. TNP-470 suppressed tumor growth of both H226B and H226Br when used at a concentration of 100 mg/kg. However, at this dose, TNP-470 caused a marked reduction in body weight, presumably due to toxicity. On the other hand, TNP-470 suppressed the growth of H226Br tumor when used at a concentration of 30 mg/kg without producing a marked effect on body weight.
We also investigated the anti-angiogenic effects of TNP-470 in these tumors by immunohistochemical staining using DAKO EPOS anti-von Willebrand factor antibody. A marked degree of neovascularization was noted in H226Br tumors, although H226B tumors showed a lower degree of angiogenesis. TNP-470 suppressed tumor vascularization at a dosage that was not associated with toxicity. To investigate the mechanism of the anti-angiogenic effect of TNP-470, we quantitated the expression of angiogenic factors on H226B and H226Br cells. In our in vitro experiments, we demonstrated a strong expression of PD-ECGF on H226Br cells compared to H226B cells. In contrast, the expression levels of VEGF on these cell lines were similar.
PD-ECGF is identical to dThdPase, 10) and PD-ECGF/ dThdPase exhibits angiogenic activity. 11, 12) Angiogenesis is an important factor in cancer progression. 18) Previous studies have shown that PD-ECGF/dThdPase is expressed in gastric, lung, breast, and bladder cancers. [13] [14] [15] [16] 30) PD-ECGF/dThdPase is also expressed in normal tissues, macrophages, stromal cells, glial cells, and some epithelia. 17) In cancer tissues, its expression plays an important role in tumor growth and metastasis, and influences prognosis. 1, 15, 18, 25) In our in vitro experiments, TNP-470 inhibited cell growth of H226Br and H226B at concentrations of 1 and 10 µg/ml. H226Br cells expressed PD-ECGF/dThdPase and this expression was suppressed by TNP-470 at concentrations of 0.1, 1 and 10 µg/ml, yet the expression of PD-ECGF in H226B cells was not suppressed by TNP-470. These results indicate that TNP-470 suppresses the proliferation of H226Br cells and also suppresses the expression of PD-ECGF at lower concentrations.
To estimate the in vivo expression of angiogenic factors, we carried out immunoblot analysis of PD-ECGF and VEGF. The expression of PD-ECGF was weak in H226Br tumors treated with TNP-470 compared to tumors of untreated mice. The expression of PD-ECGF was also found in H226B tumors, but TNP-470 treatment did not influence the expression. To investigate further the mechanism of the anti-angiogenic effect of TNP-470 in vivo, we measured the activity of PD-ECGF/dThdPase in H226Br tumors. The activity of this enzyme in H226Br tumor was suppressed by TNP-470 at a concentration of 30 mg/kg. In vivo expression levels of PD-ECGF in H226B and H226Br were similar according to the results of activity and immunoblot analysis, although differences in PD-ECGF expression were noted between these cell lines in in vitro experiments. One possible explanation of this result is that in vivo samples taken from tumors contained stromal tissue. Infiltrating cells and stromal cells could be sources of PD-ECGF, 17) and this may account for the apparently similar levels of PD-ECGF expression in H226B and H226Br tumors on day 56. During tumor development the production of angiogenic factor by cancer cells might be most important for neoangiogenesis, and the downregulation of PD-ECGF in H226Br by TNP-470 resulted in the difference in tumor growth and angiogenesis. A significant difference in the size of H226Br tumors was observed between TNP-470-treated and untreated groups. This corresponded well with the result of the in vitro experiment showing that TNP-470 only suppresses the expression of PD-ECGF in H226Br, but not in H226B. The expression of VEGF was not altered by TNP-470 either in vivo or in vitro. These results suggest that downregulation of PD-ECGF is a possible underlying mechanism of the anti-angiogenic effect of TNP-470 in vivo.
Another question raised by the results of these experiments is why TNP-470 suppresses the expression of PD-ECGF in H226Br, but not in H226B. H226Br was established from a brain metastatic lesion in nude mice bearing H226B tumor. Because H226Br cells express mutant-type p53 while H226B cells express wild-type p53, we expected that a difference in VEGF expression between these cell lines caused the difference in tumor growth. Kieser et al. demonstrated that mutant p53 upregulated the expression of VEGF 31) and transfection of wild-type p53 gene downregulated VEGF expression. 32) Furthermore, downregulation of VEGF by TNP-470 was observed in vitro in a pancreatic cancer cell line. 33 ) Although H226B and H226Br have different p53 status, the expression of VEGF was similar in the two cell lines, both in vitro and in vivo, and TNP-470 did not alter the expression of this angiogenic factor. Therefore, we examined the expression of other angiogenic factors in vitro. Surprisingly, H226Br cells expressed more PD-ECGF than H226B cells, and TNP-470 only downregulated the expression of PD-ECGF in H226Br cells. This result was consistent with a report that the frequency of dThdPase expression was significantly lower in p53-negative (wild-type) colorectal carcinomas than in positive (mutant-type) carcinomas.
34) The immunoblot experiment using the same samples and a different probe convincingly demonstrated that TNP-470 suppressed the expression of PD-ECGF only in H226Br but not in H226B both in vitro and in vivo.
TNP-470 clearly has other actions against tumor growth. Cell cycle arrest of endothelial cell is one of its reported effects. The importance of our study is the finding of a differential effect of TNP-470 on the growth of these two cell lines. The molecular mechanism of this difference is not known yet. A recent study revealed that methionine aminopeptidase 2 was one of the targets of TNP-470.
35) The inhibition of myristoylation of nitric oxide synthase was also suggested as a possible mechanism of the anti-angiogenic effect of TNP-470. 26 ) These targets could be related to the different actions of TNP-470 against the two cell lines. To explain this cell line-specific alteration of PD-ECGF expression by TNP-470 we have to examine the molecular mechanism of the expression of PD-ECGF at the transcriptional and translational levels in H226Br under the conditions of TNP-470 treatment.
In conclusion, we have demonstrated in this study that TNP-470 inhibited tumor cell proliferation and tumor growth of human lung cancer cells by inhibiting the formation of new blood vessels within growing tumors. This anti-angiogenic factor also suppressed the expression of PD-ECGF/dThdPase enzyme. Our results indicated that this suppression plays an important role in the anti-tumor and anti-angiogenic effects of TNP-470 in vivo. March 24, 2000) 
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